NCT01306578View on ClinicalTrials.gov

Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions
Guillain Barre Syndrome
Interventions
DRUG

IVIG

Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days

PROCEDURE

Plasma Exchange

Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days

Trial Locations (1)

Unknown

Mansoura University Children Hospital, Al Mansurah

All Listed Sponsors
lead

Mansoura University Children Hospital

OTHER

NCT01306578 - Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) | Biotech Hunter | Biotech Hunter